Skip to content

Study · In vitro (cells) · 2011

3 results

[An experimental study on the regulation of bone marrow-derived mesenchymal stem cells through indoleamine 2,3-dioxygenase signaling pathway by thymosin α1 for improving the immunosuppression mediated by T cell].

Hou F, Huang JM, Zhang R, Li L, Li G

Zhonghua er ke za zhi = Chinese journal of pediatrics1 Mar 2011Cited by 2 (Europe PMC)

PMID21575365 (opens in a new tab)DOI10.3760/cma.j.issn.0578-1310.2011.03.005 (opens in a new tab)PepBankPUB-21575365
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In bone marrow MSCs from children with aplastic anemia, Tα1 downregulated TLR9 expression in a concentration- and time-dependent manner.

    In plain wordsIn lab tests, thymosin alpha‑1 lowered TLR9 expression compared with untreated cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTLR9 expression in AA MSCs
    Study

    humann: not reported in source

    Bone marrow mesenchymal stem cells from children with aplastic anemia
    Comparator
    Untreated AA MSCs
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AA MSCs obviously expressed TLR9, but not IDO; AA MSCs treated with Tα1 downregulated TLR9 expression but upregulated IDO expression in concentration- and time-dependent manners.
    1 context sentence
    Summary · context
    To study the regulatory effect of thymosin α1 (Tα1) on immunosuppression of bone marrow mesenchymal stem cells (MSCs) from children with aplastic anemia (AA) through Toll-like receptor 9(TLR9)and indoleamine 2,3-dioxygenase (IDO) signaling pathway.
  2. 02LabIn vitro (cells)Mechanism

    In bone marrow MSCs from children with aplastic anemia, Tα1 upregulated IDO expression in a concentration- and time-dependent manner.

    In plain wordsIn lab tests, thymosin alpha‑1 raised IDO expression compared with untreated cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIDO expression in AA MSCs
    Study

    humann: not reported in source

    Bone marrow mesenchymal stem cells from children with aplastic anemia
    Comparator
    Untreated AA MSCs
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AA MSCs obviously expressed TLR9, but not IDO; AA MSCs treated with Tα1 downregulated TLR9 expression but upregulated IDO expression in concentration- and time-dependent manners.
    1 context sentence
    Summary · context
    To study the regulatory effect of thymosin α1 (Tα1) on immunosuppression of bone marrow mesenchymal stem cells (MSCs) from children with aplastic anemia (AA) through Toll-like receptor 9(TLR9)and indoleamine 2,3-dioxygenase (IDO) signaling pathway.
  3. 03LabIn vitro (cells)Activity measurement

    In cocultures with bone marrow MSCs from children with aplastic anemia, MSCs treated with Tα1 for 18 h inhibited T cell proliferation more strongly than untreated AA MSCs.

    In plain wordsIn lab tests, stem cells with aplastic anemia held back T cell growth more after thymosin alpha‑1 than without it.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseInhibition of T cell proliferation by AA MSCs
    Study

    humann: not reported in source

    Bone marrow mesenchymal stem cells from children with aplastic anemia
    Comparator
    Untreated AA MSCs
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 18 hoursAs given in this study (human).

    Measurements

    T cell proliferation inhibition
    42.83%
    AA MSCs with Tα1 18 h
    T cell proliferation inhibition
    21.38%
    AA MSCs untreated

    Source sentences

    Summary
    The inhibition of AA MSCs on T cell proliferation (21.38% ± 12.34%) was lower than that in normal individuals (62.72% ± 17.79%, P < 0.05), while AA MSCs treated with Tα1 for 18 h exhibited a stronger inhibition (42.83% ± 16.54%, P < 0.05).
    1 context sentence
    Summary · context
    To study the regulatory effect of thymosin α1 (Tα1) on immunosuppression of bone marrow mesenchymal stem cells (MSCs) from children with aplastic anemia (AA) through Toll-like receptor 9(TLR9)and indoleamine 2,3-dioxygenase (IDO) signaling pathway.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.